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From the diagnostic perspective, pancreatic
cancer is a rare tumor.  However, from a mor-
tality perspective, pancreatic cancer is one of
the  deadliest.    In  fact,  pancreatic  cancer  is
fourth  among  the  leading  causes  of  cancer-
related death in the United States, following
lung,  colon,  and  breast,  and  followed  by
prostate cancer.  In the United States in 2010,
estimates show that 43,100 individuals will be
diagnosed with pancreatic cancer, and 36,800
lives will be lost.  The similarity of these num-
bers is a stark reminder that the five-year sur-
vival rate for pancreatic cancer is a dismal 6%.
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The  Pancreatic  Cancer  Action  Network
(http://pancan.org/)  was  founded  in  1999  by
three  visionaries  as  a  small,  non-profit,
501(c)(3)  patient-based  advocacy  organiza-
tion.  The mission of the Pancreatic Cancer
Action Network is to advance research, support
patients, and create hope for those affected by
pancreatic cancer.  These goals are addressed
by a comprehensive approach, including direct
funding of scientific and clinical research proj-
ects,  raising  money  and  awareness  through
community outreach, educating and support-
ing patients and their caregivers, and advocat-
ing for increased federal funding for pancreat-
ic cancer research.
An  important  program  at  the  Pancreatic
Cancer  Action  Network  is  the  Patient  and
Liaison Services (PALS). PALS associates are
available  by  phone  or  e-mail  to  answer
patients’ and caregivers’ queries about their
diagnosis, treatment, symptom management,
etc.  Free  educational  packets  are  promptly
mailed  to  callers.    The  PALS  program  also
maintains a database of IRB-approved pancre-
atic cancer clinical trials throughout the coun-
try, helping patients navigate through difficult
decisions  regarding  their  treatment  options.
Finally, a Survivor and Caregiver Network con-
nects those currently facing pancreatic cancer
to volunteers who have already experienced it,
either themselves or caring for a loved one,
providing support and inspiration to those bat-
tling the disease.
The  Pancreatic  Cancer  Action  Network
takes great pride in its grants program, having
distributed  56  grants  for  over  $7.2  million
since  the  program’s  inception  in  2003.
Applications for the 2011 grants program will
be accepted starting in the fall 2010.  Nearly $3
million will be awarded this year, representing
a 30% increase from last year’s funding.  The
overarching goal of the grants program is to
attract and retain bright scientists to the study
of  pancreatic  cancer,  and  support  their
research  endeavors.    Grants  are  specifically
dedicated to researchers early in their careers
(Fellowship, Career Development, or Pathway
to Leadership Awards) or those taking a some-
what  unconventional  research  approach
(Innovative Awards). Broader efforts are also
made to connect early-career scientists with
more  senior  mentors,  foster  collaborations,
and provide education and other career sup-
port, in order to expand and strengthen the
pancreatic cancer research community.  More
information about the grants program can be
found at: http://pancan.org/section_research/.
Funding  efforts  made  by  the  Pancreatic
Cancer  Action  Network  comprise  a  small,
focused  portion  of  the  pancreatic  cancer
research investment, with the National Cancer
Institute (NCI) acting as the largest funder.
Although pancreatic cancer is a leading cancer
killer in this country (a remarkable fact given
that it is relatively rare), it receives a small
fraction of the NCI’s research budget.  The his-
torical discrepancy between funding for pan-
creatic cancer and that for the other top five
cancer killers suggests a strong direct propor-
tionality between funding and survival rates
(Figure 1). In order to effect change and see
progress, it is essential that the NCI create tar-
geted, strategic plans to combat the deadliest
cancers.  
In  addition  to  advocating  specifically  for
pancreatic  cancer  research,  the  Pancreatic
Cancer Action Network also leads an effort to
develop a federally funded research program
for the deadliest cancers, those with five-year
survival rates of less than 50%. It is worth not-
ing that most of the tumors represented by this
Deadly Cancer Coalition are also rare.
Anyone  devoting  their  time,  money,  and
intellectual  focus  to  rare  tumors  should  be
applauded.  Although  perhaps  not  as  uncom-
mon  as  some  of  the  diseases  studied  by
authors and readers of this journal, pancreatic
cancer  still  remains  drastically  understudied
and underfunded, relative to its public health
toll.  The Pancreatic Cancer Action Network
strives to accelerate research progress towards
early  detection,  prevention,  and  therapeutic
options for this devastating disease.  
Thank you very much for the opportunity to
highlight our organization and its mission in
this important journal.  Please feel free to con-
tact  us  with  inquiries,  submissions  to  our
grants program, or to refer patients for infor-
mation.  
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